JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance

  • 0Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
American Journal of Hematology +

|

January 28, 2025

|

January 28, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

TP53 mutations (TP53 MUT) significantly impact survival in myeloproliferative neoplasms (MPN). Multihit TP53 MUT in MPN blast/accelerated phase or MF-CP indicates poor prognosis, while non-multihit TP53 MUT may not affect short-term survival in MF-CP, PV, or ET.

Area Of Science

  • Hematology
  • Oncology
  • Molecular Biology

Background

  • The clinical significance of TP53 mutations (TP53 MUT) in myeloproliferative neoplasms (MPN) and their prognostic impact based on MPN subtype remains understudied.
  • TP53 mutations are associated with adverse outcomes in various hematologic malignancies, but their specific role in different MPN subtypes requires detailed investigation.

Purpose Of The Study

  • To systematically evaluate the clinical relevance and prognostic interaction of TP53 mutations with MPN subtype designation.
  • To assess the impact of TP53 mutation complexity (multihit vs. non-multihit) on overall survival (OS) and outcomes following allogeneic stem cell transplant (ASCT).

Main Methods

  • Retrospective analysis of 114 patients with MPN harboring TP53 mutations (VAF ≥ 2%).
  • Evaluation of overall survival (OS) from the time of TP53 mutation detection across different MPN subtypes: chronic phase myelofibrosis (MF-CP), blast-phase (MPN-BP), accelerated-phase (MPN-AP), and polycythemia vera/essential thrombocythemia (PV/ET).
  • Classification of TP53 mutations as multihit or non-multihit based on International Consensus Classification (ICC) criteria; assessment of karyotype (monosomal/complex).

Main Results

  • MPN-BP and MPN-AP patients with TP53 MUT had dismal OS (median 4-6 months), significantly inferior to TP53 wild-type MPN-BP/AP (median 11 months).
  • In MF-CP, multihit TP53 MUT was associated with significantly shorter OS (median 10 months) compared to non-multihit TP53 MUT (median 35 months), independent of other genetic factors.
  • Multihit TP53 MUT correlated with inferior survival post-ASCT (median 9 months) versus no multihit TP53 MUT (not reached).

Conclusions

  • The presence of multihit TP53 MUT in MPN-BP/AP or MF-CP portends an exceptionally poor prognosis and supports classification within 'myeloid neoplasms with mutated TP53'.
  • Non-multihit TP53 MUT alone may not significantly compromise short-term survival in MF-CP, PV, or ET.
  • These findings highlight the critical role of TP53 mutation complexity in stratifying MPN patient risk and guiding therapeutic strategies.

Keywords:

Related Concept Videos

Abnormal Proliferation 02:23

4.4K

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Cancer-Critical Genes II: Tumor Suppressor Genes 01:05

7.3K

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

Negative Regulator Molecules 01:23

35.1K

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.

Three of the best-understood negative regulators are p53, p21, and retinoblastoma protein (Rb). The regulatory roles of each of these proteins were discovered after faulty copies were found in cells with uncontrolled replication (i.e.,...